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Abstract 
Abnormally increased skeletal-muscle-specific E3 ubiquitin ligase (MG53) is associated with the inhibition of insulin 
signalling and insulin resistance (IR) in animal models. Four community-based studies of Han Chinese populations 
were included in this study to test the association of variants of MG53 and type 2 diabetes (T2D). The results showed 
that rs7186832 and rs12929077 in MG53 were significantly associated with T2D and impaired fasting glucose (IFG) of 
females in the discovery-stage case–control study and cohort study respectively of rural population but not in the 
replication sample of urban population. In rural population, the fasting insulin (mU/L) of the subjects with AA, AG and 
GG genotypes in rs12929077 were 8.70 ± 8.05, 10.71 ± 11.16 and 13.41 ± 14.26, respectively, and increased linearly in 
T2D cases without medication treatment (P = 0.04). This variant was significantly associated with HOMA-IR (P = 0.020) 
and HOMA-IS (P = 0.023). In individuals with IFG, the insulin and HOMA-IR of AG carriers were significantly higher 
than those of AA carriers. In urban population, after glucose loading, there were significant differences in the 30-min 
glucose, the area under the curve (AUC) of 30-min glucose and the AUC of 120-min glucose according to the geno-
types of rs7186832 and rs12929077 in males but not females. Our findings suggest that MG53 variants might confer 
risk susceptibility to the development of T2D of females and IR particularly in rural population.
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Background
Diabetes affects approximately 10 % of the world’s adult 
population and is one of the leading risk factors for car-
diovascular disease, renal failure and visual impairment 
(Shaw et  al. 2010; van Dieren et  al. 2010). Of all of the 
categories of diabetes, type 2 diabetes mellitus (T2D) 
accounts for approximately 90 %. In recent decades, the 
prevalence of T2D has increased rapidly due to ageing 
of the population, urbanization and lifestyle changes, 
making it one of the most important public health chal-
lenges in China (Xu et al. 2008; Wong and Wang 2006). 
Although the increase in T2D prevalence is caused by 
environmental factors, there is considerable evidence 
that T2D is highly heritable (Pyke 1979; Sandler 1984; 
Jirkovska 1989). Genome-wide association studies have 
identified a number of susceptibility loci associated 
with T2D (Tsai et al. 2010; Sladek et al. 2007; Scott et al. 
2007). However, these loci account for only some of the 
genetic variants in T2D, suggesting that much remains to 
be discovered. Further research should reveal additional 
genetic factors based on the understanding of the mecha-
nisms that are involved in the development of T2D.
Insulin resistance (IR), defined as decreased glucose 
uptake and disposal ability, along with defects in insu-
lin secretion, are fundamental elements in the aetiology 
of T2D. In the early stage of the disease, IR is highest in 
skeletal muscle (Kahn 1994), which accounts for approxi-
mately two-thirds of glucose utilization after meals. Sev-
eral studies have demonstrated that insulin receptor, 
insulin receptor substrate 1 (IRS1) and kinase activities 
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are decrease in the muscles of early-T2D patients (Good-
year et al. 1995; Caro et al. 1987), suggesting that insulin 
receptor and IRS1 play important roles in the insulin sig-
nalling pathway (Hepp 1980). Further studies have shown 
that insulin binds insulin receptor and then activates IRS 
protein tyrosine phosphorylation immediately after ini-
tiating insulin’s downstream effects, including the acti-
vation of phosphatidylinositol 3-kinase (PI3K) and the 
translocation of glucose transporter 4 (Frattali et al. 1991; 
Murakami and Rosen 1991; Ma et  al. 2013). In contrast 
to the glucose tolerance change observed in IRS1 tissue-
specific knockout mice (Bruning et  al. 1998), animals 
with muscle-specific insulin receptor knockout exhib-
ited features of T2D without a change in glucose toler-
ance. Therefore, IR in skeletal muscle may be a key player 
in the development of T2D, but the mechanisms that are 
involved in skeletal muscle IR remain uncertain.
Recently, a report published in Nature has proposed 
a new mechanism underlying IR in skeletal muscle and 
metabolic syndrome, identifying a novel role of Mit-
sugumin 53 (MG53) as a muscle-specific E3 ubiquitin 
ligase targeting insulin receptor and IRS1 (Song et  al. 
2013). The specific inhibition of the E3 ubiquitin ligase of 
MG53 prevents the degradation of insulin receptor and 
IRS1 and indicate that MG53, acting as an E3 ubiquitin 
ligase, is a key negative regulator of insulin signal in skel-
etal muscle and that the overexpression of MG53 con-
fers a risk of metabolic disorders (Song et al. 2013). This 
evidence provides important new insight into the patho-
physiology of T2D, but there is no report to date of evi-
dence for this association in a human population. Herein, 
we investigated the association between MG53 polymor-
phisms and T2D and IR in four community-based studies 
in Han Chinese populations.
Methods
Subjects
In the primary stage (discovery phase), our case–con-
trol study (Nantong population) consisted of 776 T2D 
patients (249 men/527 women), 522 IFG subjects (180 
men/342 women) and 957 NGT control subjects (331 
men/626 women) who were recruited to find positive 
genetic variants of MG53 for T2D. The participants 
were selected from a rural population of 14,469 subjects 
in two towns east of the Nantong City, Jiangsu prov-
ince in 2008. According to the diabetes diagnosis crite-
ria of the America Diabetes Association (ADA), IFG and 
T2D are defined by fasting plasma glucose (FPG) levels 
5.6–7.0 and ≥7.0 mmol/L, respectively, or having a self-
reported T2D history, and NGT is defined by a normal 
FPG of ≤5.6  mmol/L. A questionnaire including age, 
gender, nationality, education level, physical activity and 
household income was given to participants to gather 
demographic characteristics. The interview also included 
questions associated with the diagnosis and treatment 
of diabetes, hypertension, dyslipidemia and cardiovas-
cular events. Weight, height, blood pressure and waist 
circumference were measured twice by different trained 
staff members. BMI was calculated as the weight (in kilo-
grams) divided by the square of the height (in metres). A 
simplified version of the international physical activity 
questionnaire (IPAQ) was applied to evaluate PAI by self-
reporting of 24-h physical activity. The PAI was calcu-
lated based on the hours and metabolic energy estimate 
(MET) of physical activities, including sleeping (1 MET), 
watching TV or sitting (1.1 MET), light activity (1.5 
MET), moderate activity (4 MET), and vigorous activity 
(8 MET).
The further replication stage consisted of three study 
populations, also from Jiangsu province including a case–
control study of T2D in an Wuxi City urban population, 
a baseline survey for cardiovascular disease cohort study 
of a general rural population in Yixing City and further 
average 5.18  years follow-up (from May, 2014 to Octo-
ber, 2015) was carried out. A cross-sectional study of an 
IFG and impaired glucose tolerance (IGT) population 
subjected to an oral glucose tolerance test (OGTT) from 
the program of metabolic disease surveys in an urban 
population of Gulou District, Nanjing City. Similarly to 
the data acquired from the Nantong population, demo-
graphic information, disease history, family history of 
diabetes, behaviour profiling and anthropometric vari-
ables, except physical activity, were acquired.
The replication case–control study of the Wuxi popula-
tion was based on a community epidemiological survey, 
and unrelated ethnic Han Chinese individuals aged more 
than 30  years were enrolled. A total of 1200 T2D cases 
defined as above and 1200 age- and gender-matched 
healthy controls were included.
HOMA indices, including HOMA-IR, HOMA-IS and 
HOMA-β, which were used to assess IR, insulin sensi-
tivity and the function of islet β cells, respectively, were 
estimated from serum insulin and fasting glucose in 4222 
adults aged 30 years or more in the Yixing cohort study. 
This population included 497 T2D cases, 875 subjects of 
IFG and 2850 subjects of NGT defined as above.
During the community chronic disease survey in Gulou 
District, Nanjing City, all of the subjects aged more than 
40  years who were free of diabetes after fasting glucose 
and 2-h postprandial glucose detection accepted an 
OGTT (75 g of glucose) and venous blood samples drew 
at 0, 30 and 120 min were used to access IR and pancre-
atic islet β cell function by calculating the AUCs of fast-
ing glucose and insulin. Finally, 1932 individuals were 
diagnosed with prediabetes, and the numbers of IFG, 
IGT (2-h blood glucose was 7.8–11.1 mmol/L after 75 g 
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of glucose OGTT) and both IFG and IGT were 329, 1322 
and 281, respectively.
The methods were approved by the Nanjing Medical 
University (Nanjing) and were carried out in accordance 
with the approved relevant guidelines. All of the individ-
uals provided written informed consent before participa-
tion in the study.
Sequencing analysis of MG53
MG53 (gene ID: 493829), located on human chromo-
some 16p11.2 and spanning 14,519  bp, is conserved in 
animals. To discover single nucleotide polymorphisms 
(SNPs) of MG53, 20 Chinese healthy control subjects 
and 30 extreme phenotype patients of BMI > 30 and fast-
ing blood glucose >10  mmol/L were selected for MG53 
sequencing analysis by the Sanger sequencing method. 
Twelve pairs of primers covering the entire region of 
MG53, as well as regions 2  k upstream and 1  k down-
stream, were designed for amplification and sequencing 
analysis on the basis of GenBank sequences (Ref. Seq. 
of MG53 NC_000016). No other variant was identified 
different from the International HapMap Project (Hap-
Map Data Rel 24/phase II Nov08, on NCBI B36 assem-
bly, dbSNP b126). Thus, two tagSNPs rs7186832 and 
rs12929077 were selected and further genotyped in this 
study (Additional file 1: Figure S1).
DNA isolation and genotyping
Blood samples were collected in K3-EDTA tubes. Pro-
teinase K digestion and phenol–chloroform extrac-
tion were used to isolate genomic DNA from whole 
blood. Finally, DNA was purified and diluted to 10  ng/
μL. Genotyping was performed using TaqMan technol-
ogy and a 7900HT Fast Real-Time PCR System (Applied 
BioSystems, Foster City, CA, USA). A 5-μl reaction mix-
ture consisting of 10 ng of DNA, 2.4 μL of TaqMan uni-
versal PCR master mix, 0.1  μL of forward and reverse 
primers and FAM and VIC probes, and 1.2  μl of H2O 
were prepared for PCR reaction. The TaqMan-MGB 
probes and primers were all ordered from Applied Bio-
Systems. The genotype was determined automatically 
with the Sequence Detection System 2.1 software (95 % 
autocaller confidence level). Then, 5  % of the samples 
were repeated to determine the consistency, which was 
greater than 99.5  %. The genotype-calling success rates 
were greater than 99.9 %.
Calculations
Homeostasis model assessment (HOMA-IR, 
HOMA-β and HOMA-IS) was used to evaluate IR, 
insulin secretion and insulin sensitivity. These val-
ues were calculated using the following equations: 
HOMA-IR  =  fasting plasma glucose  ×  fasting plasma 
insulin/22.5, HOMA-β=20  ×  fasting plasma insulin/ 
(fasting plasma glucose-3.5), and HOMA-IS  =  1/(fast-
ing plasma insulin  ×  fasting plasma glucose). The unit 
of fasting plasma glucose was mmol/L, and the unit of 
fasting plasma insulin was mU/mL. The ratio of insulin 
increment to FPG increment 30 min after glucose load-
ing (ΔI30/ΔG30, insulin:glucose ratio, IGR) (Seltzer et al. 
1967), area under the curves (AUCs) for glucose and 
insulin 30 and 120  min after glucose loading, and the 
ratio of AUC of insulin and the AUC of glucose (insu-
lin release index, IRI) (Stumvoll et al. 2000) were calcu-
lated to further evaluate the first-stage islet secretory 
responses to glycaemic stimulus.
Statistical analysis
A Kolmogorov–Smirnov test was used to determine the 
normality of distribution of quantitative variables. The 
quantitative variables of non-normal distributions were 
natural logarithm transformed to obtain normal distribu-
tions for statistical analysis. Levene’s test was performed 
for homogeneity testing. Fisher’s exact test was used to 
test for HWE in the NGT control group. The genotype 
and allele distribution between cases (T2D and/or IGT 
subjects) and NGT control individuals were compared 
using Chi squared (χ2) tests. A comparison of quantita-
tive variables between different genotypes was performed 
with ANOVA, and a general linear regression was used 
to adjust for covariates. An ordinal multinomial logistic 
regression model was performed to estimate the risk of 
T2D with or without adjustment for age, gender, BMI, or 
PAI. Bonferroni correction was used for multiple compari-
sons. The odds ratio (OR) and 95  % confidence intervals 
(CI) were used to test for association in case–control study 
and the hazard ratio (HR) and 95 % CI by Cox regression 
were used to estimate the risk of IFG and T2D in cohort 
study. All of the statistical analyses were performed with 
SPSS version 15.0 (SPSS, Inc., Chicago, USA). A two-tailed 
P < 0.05 was considered statistically significant.
Results
Clinical characteristics
The demographic and clinical characteristics of the four 
studied populations are summarized in Table  1. Age 
(5  years) and gender matching were performed in the 
Nantong, Wuxi and Yixing populations. The indices of 
body mass index (BMI), systolic blood pressure (SBP), 
diastolic blood pressure (DBP), waist circumference, fast-
ing plasma glucose (FPG), fasting plasma insulin (FINS), 
homeostasis model assessment (HOMA)-IR and HOMA-
IS in the normal glucose tolerance (NGT), impaired fast-
ing glucose (IFG) and T2D groups increased linearly, and 
the physical activity index (PAI) and HOMA-β decreased 
linearly (Ptrend < 0.05).
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Genetic association analyses of case–control study
In Nantong population, both rs7186832 and rs12929077 
were confirmed to be in Hardy–Weinberg equilibrium 
(HWE) in the control group (P  >  0.05). As shown in 
Table  2, the additive (TT vs TC vs CC) and dominant 
(TT vs TC + CC) models of rs7186832 were significantly 
associated with T2D in the Nantong population after 
adjusting for BMI, age, gender and PAI. The ORs (95 % 
CIs) were 1.31 (1.10–1.57) and 1.21 (1.03–1.40), and the 
P values were 0.014 and 0.003, respectively. After Bon-
ferroni correction, the dominant model of rs7186832 
remained statistically significant (P  =  0.003  ×  6). The 
AG and GG genotypes (dominant) of rs12929077 carrier 
showed significant risk of T2D than AA genotype carrier 
and the OR (95  % CI) was 1.18 (1.02–1.39), P =  0.049, 
after adjustment for age, gender, BMI and PAI.
Further stratification analysis by gender showed that 
the dominant models of rs7186832 and rs12929077 were 
significantly associated with T2D in the female popula-
tion, and the ORs (95 % CIs) were 1.58 (1.27–1.96) and 
1.34 (1.08–1.65) with P values of 3.9 ×  10−5 and 0.006, 
respectively (Table 3). The association strength of the two 
SNPs with T2D in females was even higher than that in 
the whole population, whereas no association was found 
in the males.
A further assessment of the association of rs7186832 or 
rs12929077 and T2D was performed in the Wuxi popula-
tion, in which the association was not significant in this 
population and stratification analysis by gender (P > 0.05, 
Table 4).
Genetic association analyses of cohort study
In Yixing population, 3490 subjects (84.5  %) were fol-
lowed, 364 (12.7  %) subjects with NGT were developed 
to IFG and 53 (1.9  %) were developed to T2D. 110 
(12.1 %) subjects with IFG were developed to T2D. Cox 
regression analyses showed that there was no significant 
association detected between rs7186832 or rs12929077 
and the risk of T2D developing from NGT or IFG (Addi-
tional file 1: Table S1). The variation of TC + CC (vs. TT) 
of rs7186832 and AG/GG (vs. AA) were significantly 
associated with the risk of IFG developing from NGT 
in females but not in males after adjustment for age and 
BMI, and the HRs (95  % CIs) were 1.556 (1.184–2.045) 
and 1.481 (1.127–1.948) with P values of 0.002 and 0.005, 
respectively (Table 5).
Quantitative trait analysis
Quantitative traits of FPG, insulin, HOMA indices and 
IRS1 were analyzed according to the genotype of MG53.
In Yixing population, a linear increase in insulin was 
observed with the variants of rs12929077 (P  =  0.013) 
in untreated T2D cases, and the insulin concentration 
in the subjects with AA, AG and GG genotypes was 
8.70  ±  8.05, 10.71  ±  11.16 and 13.41  ±  14.26  mU/L, 
respectively. Both HOMA-IR and HOMA-IS according 
to the rs12929077 genotype were significantly different, 
with P values of 0.02 and 0.023, respectively (Table 6). In 
the IFG group, AA genotype carriers of rs12929077 pre-
sented a relatively lower level of insulin and HOMA-IR 
and a higher HOMA-IS than those of the AG and GG 
genotypes.
No statistically significant difference in IRS1 levels was 
observed among the different genotypes of rs7186832 
and rs12929077 in each group or in the whole popula-
tion (Additional file  1: Table S2). A correlation analysis 
showed that IRS1 was significantly correlated with FPG 
(r = 0.131, P = 0.03) in 275 randomly selected subjects; 
Table 2 Associations of MG53 rs7186832 and rs12929077 with T2D in Nantong population
SNP single nuclear polymorphisms, WT wild type, Ht heterozygote, MT mutant type, OR odds ratio, CI confidence interval, NGT normal glucose tolerance, IFG impaired 
fasting glucose, P probability, T2D type 2 diabetes
a P value of χ2 test for comparison of genotype between case and control groups
b Ordinal multinomial logistic regression analysis adjusted for age, gender and PAI
c Ordinal multinomial logistic regression analysis adjusted for age, gender, BMI and PAI
SNP Group WT/Ht/MT Additive model (WT vs Ht vs MT) Dominant model (WT vs Ht + MT)
OR (95 % CI)a OR (95 % CI)b OR (95 % CI)c OR (95 % CI)a OR (95 % CI)b OR (95 % CI)c
rs7186832 TT/TC/CC
NGT 637/282/38 1.03 (0.89–1.18) 1.03 (0.89–1.18) 1.21 (1.03–1.40) 1.06 (0.91–1.24) 1.07 (0.91–1.26) 1.31 (1.1–1.57)
IFG 360/142/20 P = 0.717 P = 0.680 P = 0.014 P = 0.489 P = 0.439 P = 0.003
T2D 502/247/26
rs12929077 AA/AG/GG
NGT 570/343/41 0.99 (0.86–1.13) 0.99 (0.87–1.14) 1.13 (0.98–1.32) 1.01 (0.86–1.17) 1.02 (0.87–1.19) 1.18 (1.02–1.39)
IFG 320/182/16 P = 0.850 P = 0.070 P = 0.089 P = 0.968 P = 0.825 P = 0.049
T2D 459/283/29
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however, this correlation could not be replicated in the 
NGT or IFG subgroups or in the untreated T2D popu-
lation (Additional file 1: Table S3). No statistical correla-
tion was observed between IRS1 and FINS or HOMA-β, 
HOMA-IR and HOMA-IS (P > 0.05).
In the Gulou population, no significant difference in 
glucose, insulin or the indices of OGTT and HOMA 
was detected among the genotypes of MG53 SNPs 
(Additional file 1: Table S4) after glucose loading. Fur-
ther stratification analysis showed that the 30-min glu-
cose, the area under the curve (AUC) of 30-min glucose 
and the AUC of 120-min glucose increased significantly 
with the CC genotype (vs TT + TC) of rs7186832 and 
the GG genotype (vs AA + AG) of rs12929077 in males 
Table 3 Stratification analysis of MG53 rs7186832 and rs12929077 with T2D in Nantong population
SNP single nuclear polymorphisms, WT wild type, Ht heterozygote, MT mutant type, OR odds ratio, CI confidence interval, NGT normal glucose tolerance, IFG impaired 
fasting glucose, P probability, T2D type 2 diabetes
a P value of χ2 test for comparison of genotype between case and control groups
b Ordinal multinomial logistic regression analysis adjusted for age, gender and PAI
c Ordinal multinomial logistic regression analysis adjusted for age, gender, BMI and PAI
SNP Gender Group WT/Ht/MT Additive model (WT vs Ht vs MT) Dominant model (WT vs Ht + MT)
OR (95 % CI)a OR (95 % CI)b OR (95 % CI)c OR (95 % CI)a OR (95 % CI)b OR (95 % CI)c
rs7186832 TT/TC/CC
Male NGT 204/115/12 0.83 (0.65–1.05) 0.83 (0.65–1.06) 0.96 (0.74–1.24) 0.75 (0.57–0.99) 0.77 (0.58–1.02) 0.91 (0.67–1.23)
IGT 125/47/8 P = 0.121 P = 0.136 P = 0.743 P = 0.049 P = 0.071 P = 0.538
T2D 171/67/10
Female NGT 433/167/26 1.15 (0.97–1.36) 1.14 (0.97–1.36) 1.36 (1.12–1.63) 1.25 (1.03–1.53) 1.25 (1.03–1.54) 1.58 (1.27–1.96)
IGT 235/95/12 P = 0.114 P = 0.177 P = 0.001 P = 0.024 P = 0.026 P = 3.9 × 10−5
T2D 331/180/16
rs12929077 AA/AG/GG
Male NGT 184/133/14 0.84 (0.66–1.06) 0.83 (0.65–1.05) 0.94 (0.73–1.22) 0.80 (0.61–1.04) 0.80 (0.61–1.05) 0.82 (0.67–1.24)
IGT 111/63/5 P = 0.138 P = 0.124 P = 0.641 P = 0.107 P = 0.112 P = 0.580
T2D 154/85/10
Female NGT 386/210/27 1.07 (0.91–1.27) 1.09 (0.92–1.28) 1.24 (1.03–1.47) 1.12 (0.93–1.39) 1.14 (0.94–1.39) 1.34 (1.08–1.65)
IGT 209/119/11 P = 0.407 P = 0.329 P = 0.019 P = 0.225 P = 0.172 P = 0.006
T2D 305/198/19
Table 4 Associations analysis of MG53 rs7186832 and rs12929077 with T2D in Wuxi population
P value of Logistic regression for comparison of genotype between case and control groups adjusted for BMI, age and gender
SNP single nuclear polymorphisms, WT wild type, Ht heterozygote, MT mutant type, OR odds ratio, CI confidence interval, P probability, T2D type 2 diabetes
SNP Gender Group WT/Ht/MT Additive model (WT vs Ht vs MT) Dominant model (WT vs 
Ht + MT)
OR (95 % CI) P value OR (95 % CI) P value
rs7186832 Whole population Control 756/392/50
T2D 738/391/62 1.03 (0.89–1.20) 0.61 1.02 (0.85–1.21) 0.81
Male Control 289/169/19
T2D 286/159/30 1.03 (0.82–1.30) 0.75 0.97 (0.73–1.28) 0.84
Female Control 467/223/31
T2D 452/232/32 1.04 (0.86–1.26) 0.63 1.06 (0.84–1.33) 0.59
rs12929077 Whole population Control 726/409/56
T2D 716/415/69 1.04 (0.90–1.21) 0.51 1.04 (0.87–1.24) 0.65
Male Control 278/175/21
T2D 277/167/34 1.05 (0.84–1.32) 0.64 0.99 (0.75–1.31) 0.96
Female Control 448/234/35
T2D 439/248/35 1.05 (0.87–1.26) 0.60 1.08 (0.863–1.35) 0.49
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but not in females (Fig. 1). The results of stratification 
analysis by gender are listed in Additional file 1: Table 
S5.
Discussion
MG53, also known as tripartite motif 72 (TRIM72) in 
humans, is a newly identified member of the tripartite 
Table 5 Association of MG53 genotypes with the risk of IFG from NGT in Yixing cohort population
SNP single nuclear polymorphisms, HR hazard ratio, CI confidence interval, P probability
a Cox regression analysis adjusted for age, gender and BMI
b Cox regression analysis adjusted for age and BMI
SNPs Gender Additive model Dominant model
HR (95 % CI)a Pa HR (95 % CI)a Pa
rs7186832 Whole population 1.077 (0.899–1.291)a 0.421a 1.192 (0.967–1.47)a 0.1a
Male 0.821 (0.606–1.112)b 0.202b 0.819 (0.584–1.148)b 0.247b
Female 1.283 (1.022–1.611)b 0.032b 1.556 (1.184–2.045)b 0.002b
rs12929077 Whole population 1.035 (0.869–1.234)a 0.698a 1.116 (0.908–1.373)a 0.297a
Male 0.786 (0.588–1.049)b 0.102b 0.758 (0.545–1.053)b 0.098b
Female 1.247 (0.998–1.558)b 0.052b 1.481 (1.127–1.948)b 0.005b
Table 6 Comparison of FINS, FPG and HOMA indices according to the genotypes of MG53 in Yixing population
Comparison of FINS, FPG, HOMA-β, HOMA-IR, HOMA-IS between genotypes rs7186832 and rs12929077 were adjusted for age, gender and BMI by general linear 
regression; Significant P value (P < 0.05) was observed and marker by “*” for comparing AG to AA of rs12929077, a linear increase in insulin was observed with the 
variants of rs12929077 (P = 0.013) in untreated T2D subjects. FINS, HOMA-β, HOMA-IR, HOMA-IS are log-transformed for comparison
NGT normal glucose tolerance, IFG impaired fasting glucose, T2D type 2 diabetes, n number of subjects, BMI body mass index, FPG fasting plasma glucose, FINS fasting 
insulin, HOMA homeostasis model assessment, IR insulin resistance, IS insulin sensitivity
Group Variable rs7186832 rs12929077
TT TC CC AA AG GG
NGT n 1836 910 99 1681 1019 127
FINS (mU/L) 5.76 ± 4.38 5.75 ± 4.47 5.21 ± 3.90 5.77 ± 4.42 5.72 ± 4.42 5.29 ± 3.60
FPG (mmol/L) 4.89 ± 0.59 4.90 ± 0.58 4.80 ± 0.61 4.90 ± 0.59 4.89 ± 0.58 4.87 ± 0.51
HOMA-β 80.86 ± 309.33 85.29 ± 133.71 65.35 ± 110.37 80.18 ± 322.51 84.92 ± 128.53 71.46 ± 99.74
HOMA-IR 1.26 ± 0.97 1.27 ± 1.03 1.13 ± 0.90 1.27 ± 0.98 1.26 ± 1.01 1.15 ± 0.80
HOMA-IS 0.066 ± 0.099 0.066 ± 0.921 0.662 ± 0.096 0.06 ± 0.10 0.65 ± 0.86 0.65 ± 0.64
IFG n 569 281 25 520 313 36
FINS (mU/L) 7.12 ± 5.43 7.89 ± 7.30 6.80 ± 3.89 6.89 ± 4.86 8.22 ± 7.76* 6.33 ± 3.28
FPG (mmol/L) 6.02 ± 0.34 6.07 ± 0.38 5.96 ± 0.34 6.02 ± 0.34 6.07 ± 0.37 5.95 ± 0.34
HOMA-β 57.07 ± 43.80 61.48 ± 53.29 55.58 ± 33.25 55.07 ± 38.38 64.64 ± 59.11 51.18 ± 23.93
HOMA-IR 1.91 ± 1.47 2.14 ± 2.07 1.81 ± 1.06 1.85 ± 1.33 2.22 ± 2.16* 1.69 ± 0.95
HOMA-IS 0.038 ± 0.041 0.037 ± 0.047 0.034 ± 0.016 0.039 ± 0.042 0.036 ± 0.045 0.033 ± 0.017
T2D (untreated) n 230 96 15 197 119 21
FINS (mU/L) 8.99 ± 7.88 11.72 ± 13.88 13.75 ± 16.51 8.81 ± 8.05 10.66 ± 11.59* 14.29 ± 14.70
FPG (mmol/L) 9.74 ± 3.14 9.73 ± 3.36 8.67 ± 1.86 9.72 ± 3.16 9.88 ± 3.39 8.88 ± 1.67
HOMA-β 35.11 ± 39.20 48.84 ± 72.56 67.50 ± 94.10 35.31 ± 41.75 40.83 ± 51.27* 63.03 ± 78.67
HOMA-IR 4.06 ± 4.05 5.09 ± 5.90 4.79 ± 5.24 3.93 ± 4.03 4.86 ± 5.44* 5.35 ± 5.18
HOMA-IS 0.024 ± 0.028 0.020 ± 0.020 0.026 ± 0.037 0.026 ± 0.032 0.018 ± 0.017* 0.021 ± 0.021
T2D (treated) n 104 44 8 95 53 8
FINS (mU/L) 8.21 ± 6.01 10.23 ± 10.94 12.09 ± 14.30 8.47 ± 6.45 11.03 ± 13.38 8.88 ± 4.42
FPG (mmol/L) 9.27 ± 3.56 8.80 ± 3.08 9.95 ± 2.93 9.03 ± 3.27 9.25 ± 3.69 10.01 ± 2.95
HOMA-β 41.6847.68 52.81 ± 72.15 41.99 ± 53.95 45.12 ± 50.91 54.97 ± 88.74 30.30 ± 13.73
HOMA-IR 3.52 ± 3.83 3.88 ± 4.11 5.25 ± 5.64 3.40 ± 3.31 4.50 ± 5.49 4.01 ± 4.15
HOMA-IS 0.025 ± 0.029 0.026 ± 0.026 0.021 ± 0.021 0.25 ± 0.029 0.027 ± 0.026 0.016 ± 0.012
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Fig. 1 Stratification analysis showed that 30 min glucose (a1, a2), AUC of 30 min glucose (b1, b2) and AUC of 30 min glucose (c1, c2) after glucose 
load increase significantly in CC genotype (vs TT + TC) of rs7186832 carriers and GG genotype (vs AA + AG) of rs12929077 in males but not in 
females
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motif-containing (TRIM) family and is specifically 
expressed in the skeletal muscle and heart. The up-
regulation of MG53 has been observed in high-fat diet 
(HFD)-induced obese mice, db/db diabetic mice, spon-
taneously hypertensive rats and non-human primate 
models of metabolic syndrome as compared to control 
animals. Ko et  al. have confirmed that MG53 overex-
pression inhibits IRS1 phosphorylation and myogenesis 
in C2C12 myoblasts (Lee et  al. 2010), and the insulin 
receptor and IRS1 levels notably changed when the insu-
lin signal pathway is blocked. In this study, we observed 
positive association of MG53 polymorphisms and IFG 
and T2D in females in Nantong rural population but not 
in Wuxi urban populations. In Yixing rural population of 
cohort study, the association of MG53 polymorphisms 
and IFG was further replicated in females. These find-
ings support that MG53 variants might confer risk sus-
ceptibility to the development of T2D of females in rural 
population.
Furthermore, in Yixing rural population, FINS lin-
early increased with the variation of rs12929077 in the 
untreated T2D population, and differential HOMA-β, 
HOMA-IR and HOMA-IS were observed in both the 
IFG group and untreated T2D population. The above 
results verify the population-based evidence associat-
ing MG53 with HOMA-IR, HOMA-IS, and T2D in the 
Han Chinese population. The findings from the present 
study thus confirm the role of MG53 in IR (Song et  al. 
2013). In addition, the genetic effects of MG53 on islet 
beta cell secretion and regulating blood glucose function 
by OGTT were evaluated in Gulou urban population and 
the results indicated that the 30-min glucose, AUC of 
30  min glucose and AUC of 120-min glucose increased 
with the variation of rs7186832 and rs12929077 in males 
but not in females. These findings provide further evi-
dence strengthening the impact of MG53 on the develop-
ment of T2D.
We further evaluated a regional LD plot (http://www.
broadinstitute.org/mpg/snap/ldplot.php) of the two 
positive SNPs in T2D (Additional file 1: Figure S1). The 
LD values (r2) were estimated for neighbouring loci and 
rs7186832 (r2 > 0.9) and rs12929077 (r2 > 0.8). We sug-
gest that these closely linked loci need to be considered 
to further evaluate the genetic effect of MG53 in T2D.
Although the SNP rs7186832 in exon 3 is a synony-
mous variant, an online bioinformatics prediction tool 
(http://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.
cgi) indicated that the rs7186832 C  >  T variant acts in 
splicing regulation (Exon Splicing Silencer, ESS) for 
MG53, and the rs12929077 G  >  A variant is associated 
with transcription factor binding sites (TFBS) to AP2α 
(core match score  =  0.996) and BRCA (core match 
score = 0.994).
The AP2α transcription factor belongs to a family of 
three closely related nuclear proteins that regulate genes 
involved in development, apoptosis, and cell cycle con-
trol (Hilger-Eversheim et al. 2000). A previous study has 
reported that the AP2a site acts as a positive regulator on 
site 5 in SLC2A10, which encodes high-affinity glucose 
transporter 10 (GLUT10) (Segade et  al. 2005). GLUT10 
is widely expressed in adult tissues, including organs 
that play major roles in glucose homeostasis (Rothman 
et  al. 1995), and the haplotype of SLC2A10 is modestly 
associated with T2D (Lin et al. 2006). BRCA (breast can-
cer, early onset) encodes a nuclear phosphoprotein that 
plays a role in maintaining genomic stability, and a previ-
ous study has reported that after a diagnosis of, women 
breast cancer with a BRCA1 or BRCA2 mutation face a 
twofold increase in the risk of diabetes (Bordeleau et al. 
2011). These data provide considerable biologic plausibil-
ity for a role of MG53 in glucose homeostasis, insulin sig-
nal regulation and T2D.
This study did not identify the IRS1 level correlating 
with the variants of MG53 or the HOMA index. Given 
the tissue specificity of MG53 and factors affecting the 
IRS1 level in plasma (Krutzfeldt et al. 2000; Chibalin et al. 
2000), the plasma IRS1 level may only partly reflect MG53 
expression. Meanwhile, this discrepancy may indicate that 
IRS1 might not directly interfere with the genetic effects 
of MG53 on pancreatic β cell function, IR or T2D, and 
further research on IRS1 function is warranted.
Besides the potential bias in case–control studies, 
there are some limitations as follows. Owing to a lack 
of an appropriate ELISA kit and muscle tissues, plasma 
MG53 expression levels could not be detected; thus, cor-
relations between MG53 polymorphisms, MG53 expres-
sion and T2D risk could not be established in our study 
population. Regardless of the above limitation, this study 
provides updated evidence of MG53 polymorphisms, 
HOMA indices and T2D. In case of potential type I error, 
further replication study in large sample size population 
would be warranted.
Conclusively, our study constitutes an initial examina-
tion to investigate whether MG53 variants are associated 
with T2D, and the findings provide new insight into the 
molecular mechanism of MG53 involved in the patho-
genesis of T2D through the effects on pancreatic β-cell 
function and IR.
Additional file
Additional file 1. Supplementary material contains supplementary 
tables 1 to 5 and supplementary figure.
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